Prelude Capital Management’s Olema Pharmaceuticals OLMA Stock Holding History

Prelude Capital Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,133	Closed	-$94.3K	–	1315
2025 Q2	$94.3K	Buy	+22,133	New	+$98.7K	0.01%	922
2024 Q2	–	Sell	-32,700	Closed	-$370K	–	1413
2024 Q1	$370K	Buy	+32,700	New	+$422K	0.02%	785
2023 Q2	–	Sell	-16,225	Closed	-$56.3K	–	1290
2023 Q1	$56.3K	Sell	16,225 -3,726	-19%	-$15.2K	﹤0.01%	999
2022 Q4	$48.9K	Buy	19,951 +1,200	+6%	+$3.5K	﹤0.01%	1134
2022 Q3	$52K	Sell	18,751 -9,256	-33%	-$39.3K	﹤0.01%	1228
2022 Q2	$114K	Buy	28,007 +13,719	+96%	+$43.5K	﹤0.01%	1399
2022 Q1	$61K	Buy	+14,288	New	+$78.7K	﹤0.01%	1476

Other funds holding OLMA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prelude Capital Management's OLMA Position: Q3 2025 in Review

Prelude Capital Management sold out of Olema Pharmaceuticals (OLMA) in Q3 2025, closing a stake of 22,133 shares — an estimated $94.3K sold.

Prelude Capital Management first reported a position in OLMA in Q1 2022 and held it in 7 quarters. The position peaked at $370K in Q1 2024. 126 funds tracked by Wall St. Rank hold OLMA as of Q3 2025.

Prelude Capital Management reported no remaining Olema Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 22,133 Olema Pharmaceuticals shares in Q3 2025, an estimated $94.3K.
Prelude Capital Management first reported a position in Olema Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Prelude Capital Management's Olema Pharmaceuticals position peaked at $370K in Q1 2024.
126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.